Rule 2.10 Announcement

Rule 2.10 Announcement

Rule 2.10 Announcement

Rule 2.10 Announcement


Released: 20/01/2011

20 January 2011 BIOCOMPATIBLES INTERNATIONAL PLC ("Biocompatibles" or the "Company")

Rule 2.10 Announcement

In accordance with Rule 2.10 of the City Code on Takeovers and Mergers, Biocompatibles International plc ("Biocompatibles") announces that it has issued 1,583,291 ordinary shares of 21 53/94 pence.

Accordingly, the issued securities of Biocompatibles comprises 40,965,665 ordinary shares of 21 53/94 pence.

The ISIN for the ordinary shares is GB00B0L2JD04.

Contact:

Biocompatibles +44 (0)1252 732645

Ian Ardill, Finance Director

Lygia Jones, Assistant Company Secretary

Dealing Disclosure Requirements

Following the announcement made on Monday, 20 September 2010 that the Company

is in an offer period for the purposes of the Takeover Code, the Company is

required to restate the following:

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of

any class of relevant securities of an offeree company or of any paper offeror

(being any offeror other than an offeror in respect of which it has been

announced that its offer is, or is likely to be, solely in cash) must make an

Opening Position Disclosure following the commencement of the offer period and,

if later, following the announcement in which any paper offeror is first

identified. An Opening Position Disclosure must contain details of the person's

interests and short positions in, and rights to subscribe for, any relevant

securities of each of (i) the offeree company and (ii) any paper offeror(s). An

Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be

made by no later than 3.30 pm (London time) on the 10th business day following

the commencement of the offer period and, if appropriate, by no later than 3.30

pm (London time) on the 10th business day following the announcement in which

any paper offeror is first identified. Relevant persons who deal in the

relevant securities of the offeree company or of a paper offeror prior to the

deadline for making an Opening Position Disclosure must instead make a Dealing

Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1%

or more of any class of relevant securities of the offeree company or of any

paper offeror must make a Dealing Disclosure if the person deals in any

relevant securities of the offeree company or of any paper offeror. A Dealing

Disclosure must contain details of the dealing concerned and of the person's

interests and short positions in, and rights to subscribe for, any relevant

securities of each of (i) the offeree company and (ii) any paper offeror, save

to the extent that these details have previously been disclosed under Rule 8. A

Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no

later than 3.30 pm (London time) on the business day following the date of the

relevant dealing. If two or more persons act together pursuant to an agreement

or understanding, whether formal or informal, to acquire or control an interest

in relevant securities of an offeree company or a paper offeror, they will be

deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by

any offeror and Dealing Disclosures must also be made by the offeree company,

by any offeror and by any persons acting in concert with any of them (see Rules

8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant

securities Opening Position Disclosures and Dealing Disclosures must be made

can be found in the Disclosure Table on the Takeover Panel's website at

www.thetakeoverpanel.org.uk, including details of the number of relevant

securities in issue, when the offer period commenced and when any offeror was

first identified. If you are in any doubt as to whether you are required to

make an Opening Position Disclosure or a Dealing Disclosure, you should contact

the Panel's Market Surveillance Unit on +44 (0)20 7638 0129.

Biocompatibles International plc (www.biocompatibles.com)

Biocompatibles International plc is a leading medical technology company in the

field of drug-device combination products.

The Oncology Products Division supplies medical devices from facilities in

Farnham, UK and Oxford, CT. These include Drug-Eluting Bead Products which are

used in more than 40 countries for the treatment of primary liver cancer (HCC),

liver metastases from colorectal cancer, and other cancers; and Brachytherapy

products (Radiation-Delivering Seeds) which are used in the treatment of

prostate cancer. Our distribution partners include AngioDynamics Inc., Terumo

Corporation and Eisai Co. Ltd. We have a clinical collaboration agreement with

Bayer Healthcare Pharmaceuticals Inc.

Our Licensing Division includes CellMed, in Alzenau, Germany, which is

developing a Drug-Eluting Bead product for the treatment of stroke, based on

proprietary stem cell technology; a GLP-1 analogue for the treatment of

diabetes and obesity partnered with AstraZeneca; and a cosmetic Dermatology

Bead partnered with Merz Pharmaceuticals GmbH. We also have a PC Licensing

agreement with Medtronic Inc. in the field of Drug-Eluting Stents.

This news release contains forward-looking statements that reflect

Biocompatibles' current expectation regarding future events. Forward-looking

statements involve risks and uncertainties. Actual events could differ

materially from those projected herein and depend on a number of factors

including the success of Biocompatibles' research strategy, the applicability

of the discoveries made therein, the successful and timely completion of

clinical studies and the uncertainties related to the regulatory and

commercialisation processes.

vendor

Back to press releases